探索DNA倍体、基质-肿瘤比例和核型分析在II期结肠癌患者中的预后价值。

Exploring prognostic values of DNA ploidy, stroma-tumor fraction and nucleotyping in stage II colon cancer patients.

作者信息

Lou Yutong, Yang Lujing, Xu Shaojun, Tan Luxin, Bai Yanhua, Wang Lin, Sun Tingting, Zhou Lixin, Feng Li, Lian Shenyi, Wu Aiwen, Li Zhongwu

机构信息

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute, No.52 Fucheng Road, Haidian District, Beijing, China.

Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

出版信息

Discov Oncol. 2024 Jun 14;15(1):227. doi: 10.1007/s12672-024-01087-w.

DOI:10.1007/s12672-024-01087-w

PMID:38874696

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11178745/

Abstract

PURPOSE

To assess the prognostic value of three novel biomarkers, DNA ploidy, stroma-tumor fraction, and nucleotyping, seeking for more accurate stratification in stage II colon cancer.

METHODS

A total of 417 patients with complete follow up information were enrolled in this study and divided into three clinical risk groups. IHC was performed to examine MSI status. DNA ploidy, stroma and nucleotyping were estimated using automated digital imaging system. Kaplan-Meier survival curves, Cox proportional hazards regression models, and correlation analyses were carried out to process our data.

RESULTS

In the whole cohort of stage II colon cancer, nucleotyping and DNA ploidy were significant prognostic factors on OS in univariate analyses. The combination of nucleotyping and DNA ploidy signified superior OS and DFS. Difference was not significant between low-stroma and high-stroma patients. In multivariable analyses, nucleotyping and the combination of nucleotyping and DNA ploidy were proven the dominant contributory factors for OS. In the low-risk group, we found the combination of nucleotyping and DNA ploidy as the independent prognostic factor statistically significant in both univariate and multivariable, while in the high-risk group, the nucleotyping.

CONCLUSIONS

Our study has proven nucleotyping and the combination of DNA ploidy and nucleotyping as independent prognostic indicators, thus expanding the application of nucleotyping as a predictor from high risk stage II colon cancer to whole risks.

摘要

目的

评估三种新型生物标志物——DNA倍体、基质-肿瘤分数和核型分析的预后价值，以寻求对II期结肠癌进行更准确的分层。

方法

本研究共纳入417例有完整随访信息的患者，并将其分为三个临床风险组。采用免疫组化法检测微卫星高度不稳定（MSI）状态。使用自动数字成像系统评估DNA倍体、基质和核型分析。采用Kaplan-Meier生存曲线、Cox比例风险回归模型和相关性分析对数据进行处理。

结果

在整个II期结肠癌队列中，单因素分析显示核型分析和DNA倍体是总生存期（OS）的显著预后因素。核型分析与DNA倍体的联合显示出更好的总生存期和无病生存期（DFS）。低基质组和高基质组患者之间差异不显著。多因素分析中，核型分析以及核型分析与DNA倍体的联合被证明是总生存期的主要影响因素。在低风险组中，我们发现核型分析与DNA倍体的联合在单因素和多因素分析中均为独立预后因素，具有统计学意义；而在高风险组中，核型分析是独立预后因素。